Stocks Listing
ARGX.BR

argenx SE

Share
ARGX.BR
$439.62 0.85%Last Updated Oct 03 2022 03:14 PM
1D Low / 1D High
Low:$432.11
High:$445.56
1D
0.85%
5D
1.79 %
30D
4.98 %
BulletPurple
Market Cap
$24,206,134,362
1.57 %
24.2 B
BulletBlue
Volume 1D
23,693
-
23.7 K
BulletOrange
Circulating Supply
55,061,499 ARGX.BR
55.1 M

Price Chart

1D
5D
1M
6M
YTD
1Y
MAX
About

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Historical data

1D
5D
1M
6M
1Y
MAX
Day
Open - Close
Low/High
Volume
Market Cap
Show More
Market Status
Closed
BRU
Euronext Brussels
BEL
Opens in
9 hours, 1 minutes
Working Hours
Mon-Fri, 07:00 AM - 03:30 PM
Timezone
GMT+0